1-5 of 5
Xiaochuan Yang
Close
Sort by
Journal Articles

Inotuzumab Ozogamicin Is an Effective Salvage Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia with High-Risk Molecular Features, Including TP53 Loss

Xiaochuan Yang, Amber C. King, PharmD, BCOP, Charlene C. Kabel, PharmD, Christopher J. Forlenza, MD, Jae H. Park, MD, Mark B. Geyer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3888.
https://doi.org/10.1182/blood-2019-125165
Published: 2019
Journal Articles

Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML

Amy Sexauer, Alexander Perl, Xiaochuan Yang, Michael Borowitz, Christopher Gocke, Trivikram Rajkhowa, Christian Thiede, Mark Frattini, Grant E. Nybakken, Keith Pratz, Judith Karp, B. Douglas Smith, Mark Levis
Journal: Blood
Blood (2012) 120 (20): 4205–4214.
https://doi.org/10.1182/blood-2012-01-402545
Published: 2012
Includes: Supplemental data
Journal Articles

The Response of FLT3/ITD AML to FLT3 Inhibition: Apoptosis of Peripheral Blood Blasts and Differentiation of Bone Marrow Blasts

Amy Sexauer, Xiaochuan Yang, PhD, Alexander E Perl, MD, Christian Thiede, MD, Michael J. Borowitz, MD, PhD, Mark J. Levis, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 943.
https://doi.org/10.1182/blood.V118.21.943.943
Published: 2011
Journal Articles

Persistent ERK Activation in Bone Marrow Blasts May Account for the Difference in Bone Marrow Versus Peripheral Blood Response to FLT3 Inhibition in FLT3/ITD AML

Xiaochuan Yang, PhD, Amy Sexauer, Mark J. Levis, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 736.
https://doi.org/10.1182/blood.V118.21.736.736
Published: 2011
Journal Articles

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

Clinical Trials & Observations
Takashi Sato, Xiaochuan Yang, Steven Knapper, Paul White, B. Douglas Smith, Steven Galkin, Donald Small, Alan Burnett, Mark Levis
Journal: Blood
Blood (2011) 117 (12): 3286–3293.
https://doi.org/10.1182/blood-2010-01-266742
Published: 2011